Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:16:44.634Z.
Calculation as of: 2026-10-06T16:16:44.634Z.
Quote observation: 2026-10-06T16:13:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1e37222dd90dbab5e03bfa1bbf20eaf6e61690ec1e62f49524765e66f30de265
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$40.09M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$38.88M
EV/EBIT Ratio
74.57x
TTM Avg
60.42x
3Y Avg
123.40x
5Y Avg
130.57x
Market Cap
$43.14M
EV/EBIT Ratio
N/A
TTM Avg
7.97x
3Y Avg
11.01x
5Y Avg
11.01x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Filana Therapeutics, Inc. (FLNA) | $40.67M | N/A | N/A | N/A | N/A |
| Metagenomi, Inc. Common Stock (MGX)vs › | $40.09M | N/A | N/A | N/A | N/A |
| Nephros, Inc. (NEPH)vs › | $39.96M | 22.01x | 36.10x | 319.62x | 319.62x |
| Precipio, Inc. (PRPO)vs › | $41.92M | N/A | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.88M | 74.57x | 60.42x | 123.40x | 130.57x |
| BioStem Technologies, Inc. (BSEM)vs › | $43.14M | N/A | 7.97x | 11.01x | 11.01x |
| CVRx, Inc. (CVRX)vs › | $44.05M | N/A | N/A | N/A | N/A |
| Incannex Healthcare Limited (IXHL)vs › | $38.35M | N/A | N/A | N/A | N/A |
| Nano-X Imaging Ltd. (NNOX)vs › | $43.99M | N/A | N/A | N/A | N/A |
| DarioHealth Corp. (DRIO)vs › | $44.35M | N/A | 17.26x | 19.56x | 25.78x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
